Literature DB >> 1932521

Activation of cytotoxic cells by syngeneic prostate antigens in experimental autoimmune vesiculo-prostatitis.

A Casas-Ingaramo1, M Depiante-Depaoli, B Pacheco-Rupil.   

Abstract

In our experimental model of autoimmune vesiculo-prostatitis, obtained by immunization with syngeneic male accessory glands (MAG) and complete Freund's adjuvant, the presence of specific autoreactive cells with cytotoxic activity against prostate antigens was studied. The specific cytotoxicity generated in MAG immunized rats was tested using 51Cr labelled syngeneic prostate cells or labelled chicken erythrocytes coated with specific antigens (MAG homogenate or chromatographic fractions from prostate homogenate) which were used as target cells in a medium free of complement. The addition of spleen sensitized cells to prostate cells suspension produced a significant release of 51Cr in regard to normal effector cells (11.87 +/- SE 1.12 versus 1.5 +/- 0.75). Similar results were obtained when MAG-coated erythrocytes were used as target cells (10.87 +/- SE 0.62 versus 1.50 +/- 0.25). Depletion of T but no B or adherent-cells was shown to abolish the lytic effect indicating that MAG immunization provides determinants which are recognized by sensitized T-cells on cells of the prostate gland where the most severe tissue alterations were previously observed. Erythrocytes coated with chromatographic fractions obtained from prostate homogenate were used to identify the antigens triggering the lytic effect. It was demonstrated that two fractions (FI and FII) functioned as in vivo sensitizing antigens as well as in vitro activating antigens for themselves. The restimulation in vitro of sensitized cells with purified prostate fractions induces an additional lytic effect suggesting that an expansion of effector cells may take place after contacting the antigens at the prostate site.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1932521     DOI: 10.3109/08916939109006751

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  8 in total

1.  Histopathological classification criteria of rat model of chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Xianjin Wang; Shan Zhong; Tianyuan Xu; Leilei Xia; Xiaohua Zhang; Zhaowei Zhu; Minguang Zhang; Zhoujun Shen
Journal:  Int Urol Nephrol       Date:  2014-11-20       Impact factor: 2.370

Review 2.  Mechanisms in prostatitis/chronic pelvic pain syndrome.

Authors:  Michel A Pontari; Michael R Ruggieri
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

3.  Prostatein (or rat prostatic steroid binding protein) is a major autoantigen in experimental autoimmune prostatitis.

Authors:  M Maccioni; V E Rivero; C M Riera
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

Review 4.  Etiologic theories of chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Michel A Pontari
Journal:  Curr Urol Rep       Date:  2007-07       Impact factor: 3.092

5.  Pain in chronic prostatitis and the role of ion channels: a brief overview.

Authors:  Asha Caroline Cyril; Reem Kais Jan; Rajan Radhakrishnan
Journal:  Br J Pain       Date:  2021-05-19

Review 6.  Prostatitis versus pelvic pain syndrome: immunologic studies.

Authors:  Caroline Maake; Hubert John
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

Review 7.  Immunological Mechanisms Underlying Chronic Pelvic Pain and Prostate Inflammation in Chronic Pelvic Pain Syndrome.

Authors:  María L Breser; Florencia C Salazar; Viginia E Rivero; Rubén D Motrich
Journal:  Front Immunol       Date:  2017-07-31       Impact factor: 7.561

8.  Single-cell multi-omics analysis presents the landscape of peripheral blood T-cell subsets in human chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Meng Zhang; Yi Liu; Junyi Chen; Lei Chen; Jialin Meng; Cheng Yang; Shuiping Yin; Xiansheng Zhang; Li Zhang; Zongyao Hao; Xianguo Chen; Chaozhao Liang
Journal:  J Cell Mol Med       Date:  2020-10-30       Impact factor: 5.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.